


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subtitle for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 1		Complete if Known	
		Application Number	10/612,298
		Filing Date	July 2, 2003
		First named Inventor	Byron E. Anderson
		Group Art Unit	1646-1639
		Examiner name	Thomas Sweeney Heard-CHRISTOPHER GROSS
		Attorney Docket Number	093073-9001 US01
U.S. Patent Documents			

Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
G	5,753,628	Heavner et al.	5/19/1998

FOREIGN PATENT DOCUMENTS

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
G	JP	07-188282 A	Suetsuna Yoko	5/27/1995	Y	Y
	WO	92/04371	Ferring Peptide Research Partnership KB	3/19/1992		
	WO	97/13522	Gryphon Sciences	4/17/1997		
	WO	00/62791	Hisamitsu Pharmaceutical Co., Inc. et al.	10/26/2000		
	WO	01/11360	Institut für Diagnostik- Forschung GmbH an der Freien Universität Berlin	2/15/2001		Y

Examiner Signature		Date Considered	6/15/2006
-----------------------	---	--------------------	-----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 0231.


DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/612,298
				Filing Date	July 2, 2003
				First Named Inventor	Byron E. Anderson
				Group Art Unit	1646 1639
				Examiner Name	Thomas Sweeney Heard CHRISTOPHER GROSS
Sheet	1	of	4	Attorney Docket Number	093073-9001 US01

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
G		ALLURED, V.S. et al., "Structure of exotoxin A of pseudomonas aeruginosa at 3.0-Angstrom resolution," Proc. Natl. Acad. Sci (1986) 83:1320-1324
		APPELLA, D.H. et al., "Residue-based control of helix shape in beta-peptide oligomers," Nature (1997) 387(6631):381-384
		CHOE, S. et al., "The crystal structure of diphtheria toxin," Nature (1992) 357:216-222
		COOK, C.L. et al., "Simple purification methods for an alpha-Galactose-specific antibody from chicken eggs," J. Biosci. & Bioeng. (2001) 91(3):305-310
		CRAIG, C. and STITZEL, R. eds., Modern Pharmacology, Little, Brown & Co., Boston (1986) 127-133
		ELLIOTT, J.L. et al., "A quantitative study of the interactions of bacillus anthracis edema factor and lethal factor with activated protective antigen," Biochemistry (2000) 39:6706-6713
		ENDO, Y. et al., "The RNA N-glycosidase activity of ricin A-chain," J. Biol. Chem. (1988) 263:8735-8739
		FRYER, J.P. et al., "IgY antiporcine endothelial cell antibodies effectively block human antiporcine xenoantibody binding," Xenotransplantation (1999) 56:98-109
		GALILI, U., "The alpha-gal epitope (Galalpha1-3Galbeta1-4GlcNAc-R) in xenotransplantation," Biochimie (2001) 83:557-563

Examiner Signature		Date Considered	6/16/2006
-----------------------	---	--------------------	-----------


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/612,298	
			Filing Date	July 2, 2003	
			First Named Inventor	Byron E. Anderson	
			Group Art Unit	1646 → 1639	
			Examiner Name	Thomas Sweeney Heard CHRISTOPHER GROSS	
Sheet	2	of	4	Attorney Docket Number	093073-9001 US01

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
6		HALLORAN, M.M. et al., "Ley/H: an endothelial-selective, cytokine-inducible, angiogenic mediator," J. Immunol. (2000) 164:4868-4877
		KADLEC, R.P. et al., "Biological Weapons Control. Prospects and Implications for the Future," J. Am. Med. Assoc. (1997) 278(5):351-356
		KRUSZYNSKI, M. et al., "Identification of TNF-alpha binding peptides from a D-amino acid hexapeptide library that specifically inhibit TNF-alpha binding to recombinant p55 receptor," Cytokine (1999) 11(1):37-44
		LADUCA, J.R. et al., "Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases," Dermatologic Clinics (2001) 19:617-635
		LEBL, M. et al., "One-bead-one-structure combinatorial libraries," Biopolymers (Peptide Science) (1995) 37:177-198
		LETTERIO, J.J., "Murine models define the role of TGF-beta as a master regulator of immune cell function," Cytokine & Growth Factor Reviews (2000) 11:81-87
		LORD, J.M. et al., "Ribosome inactivating proteins of plants," Semin. Cell Biol. (1991) 2:15-22
		MASSAGUE, J., "How cells read TGF-beta signals," Nature Review Mol. Cell Biol. (2000) 1:169-178
		MILNE, J.C. et al., "Anthrax protective antigen forms oligomers during intoxication of mammalian cells," J. Biol. Chem. (1994) 269(32):20607-20612

Examiner Signature		Date Considered	6/16/2006
--------------------	---	-----------------	-----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/612,298	
			Filing Date	July 2, 2003	
			First Named Inventor	Byron E. Anderson	
			Group Art Unit	1646 1639	
			Examiner Name	Thomas Sweeney Heard CHRISTOPHER GROSS	
Sheet	3	of	4	Attorney Docket Number	093073-9001 US01

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
G		MOBERG, L.J. et al., "Affinity chromatography purification of type A botulinum neurotoxin from crystalline toxic complex," Appl. Environ. Microbiol. (1987) 35(5):878-880
G		MURPHY, L.A. et al., "Five alpha-D-galactopyranosyl-binding isolectins from bandeiraea simplicifolia seeds," J. Biol. Chem. (1977) 252:4739-4742
G		PINILLA, C. et al., "All-D peptides recognized by an anti-carbohydrate antibody identified from a positional scanning library," J. Mol. Biol. (1998) 283:1013-1025
G		Remington's Pharmaceutical Sciences, 18th Edition, Mack Pub. Co., Easton, PA (1990)
G		SHAPIRO, R.E. et al., "Identification of a ganglioside recognition domain of tetanus toxin using a novel ganglioside photoaffinity ligand," J. Biol. Chem. (1997) 272(48):30380-30386
		SPEIGHT, T. ed., Avery's Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics, 3rd ed. Williams and Wilkins, Baltimore (1987) 50-56
		SPIPKER, B., Guide to Clinical Studies and Developing Protocols, Raven Press Books, Ltd., New York (1984) 7-13, 54-60
		SPIPKER, B., Guide to Clinical Trials, Raven Press, Ltd., New York, (1991) 93-101
		SZEKANECZ, Z. et al., Chemokines and angiogenesis," Current Opinion in Rheumatology (2001) 13(3):202-208

Examiner Signature	<i>Chen</i>	Date Considered	6/15/2006
-----------------------	-------------	--------------------	-----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/612,298
				Filing Date	July 2, 2003
				First Named Inventor	Byron E. Anderson
				Group Art Unit	1646 1639
				Examiner Name	Thomas Sweeney Heard CHRISTOPHER WROG
Sheet	4	of	4	Attorney Docket Number	093073-9001 US01

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
G		TALLARIDA, R. et al., Principles in General Pharmacology, Springer-Verlag, New York, (1988) 18-20
I		TAYLOR, P.C., "Anti-tumor necrosis factor therapies," Current Opinion in Rheumatology (2001) 13(3):164-169
I		TSE, C.K. et al., "Preparation and characterisation of homogeneous neurotoxin type A from clostridium botulinum," Eur. J. Biochem. (1982) 122:493-500
I		WADE, D. et al., "All-D amino acid-containing channel-forming antibiotic peptides," Proc. Natl. Acad. Sci, USA (1990) 87:4761-4765

Examiner Signature		Date Considered	6/16/2006
--------------------	---	-----------------	-----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.